{"id":59074,"date":"2026-03-09T12:50:00","date_gmt":"2026-03-09T04:50:00","guid":{"rendered":"https:\/\/flcube.com\/?p=59074"},"modified":"2026-03-09T12:50:01","modified_gmt":"2026-03-09T04:50:01","slug":"haiscos-hsk39297-nmpa-filing-accepted-oral-factor-b-inhibitor-targets-paroxysmal-nocturnal-hemoglobinuria-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59074","title":{"rendered":"Haisco’s HSK39297 NMPA Filing Accepted \u2013 Oral Factor B Inhibitor Targets Paroxysmal Nocturnal Hemoglobinuria Market"},"content":{"rendered":"\n

Haisco Pharmaceutical Group Co., Ltd<\/strong> (SHE: 002653<\/a>) announced that China’s National Medical Products Administration (NMPA)<\/strong> has accepted for review<\/strong> the marketing application<\/strong> for HSK39297<\/strong>, an oral small molecule inhibitor of complement factor B (FB)<\/strong>, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)<\/strong>. The candidate represents a next-generation alternative pathway inhibitor<\/strong> with demonstrated advantages over standard-of-care eculizumab<\/strong> in anemia improvement and transfusion reduction, while offering the convenience of oral administration.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Filing Type<\/strong><\/td>Marketing authorization application (NDA)<\/td><\/tr>
Product<\/strong><\/td>HSK39297 (small molecule)<\/td><\/tr>
Target<\/strong><\/td>Complement factor B (FB) \u2013 alternative pathway inhibitor<\/td><\/tr>
Indication<\/strong><\/td>Paroxysmal nocturnal hemoglobinuria (PNH)<\/td><\/tr>
Developer<\/strong><\/td>Haisco Pharmaceutical (SHE: 002653)<\/td><\/tr>
Filing Acceptance<\/strong><\/td>March 2026<\/td><\/tr>
Review Timeline<\/strong><\/td>Priority review potential given unmet need; decision anticipated Q4 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>HSK39297 Profile<\/th><\/tr><\/thead>
Drug Class<\/strong><\/td>Small molecule complement factor B inhibitor<\/td><\/tr>
Mechanism<\/strong><\/td>Blocks alternative pathway (AP) activation and complement amplification loop by inhibiting FB activity<\/td><\/tr>
Pathway Impact<\/strong><\/td>Suppresses entire complement cascade at the amplification nexus<\/td><\/tr>
Route<\/strong><\/td>Oral administration (vs. IV eculizumab)<\/td><\/tr>
Key Advantage<\/strong><\/td>Convenience; potential for improved compliance and quality of life<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Therapeutic Differentiation vs. Eculizumab:<\/strong><\/p>\n\n\n\n

Endpoint<\/th>HSK39297<\/th>Eculizumab (Standard of Care)<\/th>Clinical Advantage<\/th><\/tr><\/thead>
Anemia Improvement<\/strong><\/td>Notable therapeutic advantage<\/td>Moderate<\/td>Superior hemoglobin recovery<\/td><\/tr>
Transfusion Requirements<\/strong><\/td>Significant reduction<\/td>Partial reduction<\/td>Greater transfusion independence<\/td><\/tr>
Fatigue Symptoms<\/strong><\/td>Marked alleviation<\/td>Variable<\/td>Enhanced patient-reported outcomes<\/td><\/tr>
Efficacy Durability<\/strong><\/td>Potentially maintainable long-term<\/td>Requires ongoing IV infusions<\/td>Sustained benefit with oral dosing<\/td><\/tr>
Subgroup Efficacy<\/strong><\/td>Consistent across age, gender, disease duration, baseline hemoglobin<\/td>Variable response<\/td>Broad patient population benefit<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pipeline Expansion & Franchise Strategy<\/h2>\n\n\n\n
Indication<\/th>Study Phase<\/th>Status<\/th>Strategic Value<\/th><\/tr><\/thead>
PNH<\/strong><\/td>NDA under review<\/td>NMPA filing accepted<\/td>Near-term revenue catalyst; proof-of-concept for complement platform<\/td><\/tr>
Lupus Nephritis<\/strong><\/td>Phase II<\/td>Ongoing<\/td>Large autoimmune market; potential best-in-class oral alternative to belimumab<\/td><\/tr>
Primary IgA Nephropathy<\/strong><\/td>Phase III<\/td>Initiating<\/td>High unmet need; complement inhibition validated by iptacopan approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Landscape<\/h2>\n\n\n\n
Factor<\/th>Market Implication<\/th><\/tr><\/thead>
PNH Market Size<\/strong><\/td>Global market ~$3-4 billion; China represents fastest-growing segment with improving diagnosis rates<\/td><\/tr>
Eculizumab Dominance<\/strong><\/td>Alexion’s Soliris\/Ultomiris (C5 inhibitors) control 90%+ market; oral alternatives gaining traction<\/td><\/tr>
Competitive Threats<\/strong><\/td>Novartis’ iptacopan (Factor B inhibitor, approved 2023) first oral entrant; Haisco targets China market leadership<\/td><\/tr>
Differentiation<\/strong><\/td>HSK39297 demonstrated superior anemia outcomes vs. eculizumab in head-to-head comparisons; pricing power potential<\/td><\/tr>
Pipeline Synergy<\/strong><\/td>Factor B platform applicable across multiple complement-mediated diseases (GN, aHUS, AMD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Outlook<\/h2>\n\n\n\n